Individual difference in drug metabolism and disposition:: Toxicological significance of genotypes and phenotypes of S-mephenytoin 4′-hydroxylase (CYP2C19)

被引:1
|
作者
Ikebuchi, J [1 ]
Yamada, M [1 ]
Ogura, Y [1 ]
Yamamoto, Y [1 ]
Nishimura, A [1 ]
Nishi, K [1 ]
Yamada, K [1 ]
Irizawa, Y [1 ]
机构
[1] Tottori Univ, Fac Med, Dept Legal Med, Yonago, Tottori 6830826, Japan
来源
PROGRESS IN FORENSIC GENETICS 9 | 2003年 / 1239卷
关键词
CYP2C19; genotyping; phenotyping; polymorphism; toxicogenetics;
D O I
10.1016/S0531-5131(02)00389-8
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
We examined the relationship between the genetic polymorphism of CYP2C19 and metabolism of omeprazole in order to assess the severity and to predict the outcome of poisoning for forensic and clinical toxicology. The genotypes observed were CYP2C19*1A (wild type), CYP2C19*2 (ml), and CYP2C19*3 (m2). The omeprazole hydroxylation index of the wild-type was -1.15, whereas for the hetero-type it was -0.78, and homo-mutated type 1.22. The genotype of CYP2C19 correlated with the phenotype. The present results proved that genotyping assays of drug metabolizing enzymes are of great value in toxicological significance. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:589 / 592
页数:4
相关论文
共 50 条
  • [31] Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes
    Miura, M
    Tada, H
    Yasui-Furukori, N
    Uno, T
    Sugawara, K
    Tateishi, T
    Suzuki, T
    CHIRALITY, 2005, 17 (06) : 338 - 344
  • [32] Metabolism disposition of lansoprazole in relation to the CYP2C19 phenotype status
    fu, liangqing
    wu, dezheng
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 224 - 224
  • [33] Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population
    Bathum, L
    Skjelbo, E
    Mutabingwa, TK
    Madsen, H
    Horder, M
    Brosen, K
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 48 (03) : 395 - 401
  • [34] Effects of allicin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes
    Yang, Li-Jun
    Fan, Lan
    Liu, Zhao-Qian
    Mao, Yan-Mei
    Guo, Dong
    Liu, Li-Hui
    Tan, Zhi-Rong
    Peng, Liang
    Han, Chun-Ting
    Hu, Dong-Li
    Wang, Dan
    Zhou, Hong-Hao
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (06) : 601 - 608
  • [35] Effect of glycyrrhizin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes
    Tu, J. -H.
    Hu, D. -L.
    Dai, L. -L.
    Sun, Y.
    Fan, L.
    Zhang, M.
    Tan, Z. -R.
    Chen, Y.
    Li, Z.
    Zhou, H. -H.
    XENOBIOTICA, 2010, 40 (06) : 393 - 399
  • [36] Effects of allicin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes
    Li-Jun Yang
    Lan Fan
    Zhao-Qian Liu
    Yan-Mei Mao
    Dong Guo
    Li-Hui Liu
    Zhi-Rong Tan
    Liang Peng
    Chun-Ting Han
    Dong-Li Hu
    Dan Wang
    Hong-Hao Zhou
    European Journal of Clinical Pharmacology, 2009, 65 : 601 - 608
  • [37] EFFECTS OF ALLICIN ON CYP2C19 AND CYP3A4 ACTIVITY IN HEALTHY VOLUNTEERS WITH DIFFERENT CYP2C19 GENOTYPES
    Yang, Li-Jun
    Zhou, Hong-Hao
    DRUG METABOLISM REVIEWS, 2008, 40 : 35 - 35
  • [38] Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations
    Inoue, K
    Yamazaki, H
    Imiya, K
    Akasaka, S
    Guengerich, FP
    Shimada, T
    PHARMACOGENETICS, 1997, 7 (02): : 103 - 113
  • [39] The effect of perazine on the CYP2D6 and CYP2C19 phenotypes as measured by the dextromethorphan and mephenytoin tests in psychiatric patients
    Baumann, Pierre
    Eap, Chin B.
    Gastpar, Markus
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2020, 126 (05) : 444 - 447
  • [40] A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin
    Ibeanu, GC
    Blaisdell, J
    Ferguson, RJ
    Ghanayem, BI
    Brosen, K
    Benhamou, S
    Bouchardy, C
    Wilkinson, GR
    Dayer, P
    Goldstein, JA
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1999, 290 (02): : 635 - 640